TIDMAGL
RNS Number : 1632B
Angle PLC
08 January 2018
For immediate release 8 January 2018
ANGLE plc ("the Company")
RESEARCH DEMONSTRATES USE OF PARSORTIX(TM) LIQUID BIOPSY TO
DETECT ARV7 IN PROSTATE CANCER AS A TREATMENT SELECTION
BIOMARKER
Parsortix-based ARV7 test may provide a wider understanding of
ARV7 than other techniques with the potential for improved patient
outcomes
Independent research estimates that an ARV7 test could save, on
average, at least $5,000 per patient tested
ANGLE plc (AIM:AGL OTCQX:ANPCY), a world-leading liquid biopsy
company, is delighted to announce that the University Medical
Centre Hamburg-Eppendorf (UKE) together with the Medical University
of Graz (Graz) and the Science for Life Laboratory, Stockholm
University (SciLifeLab) have published results of work
demonstrating that ANGLE's Parsortix(TM) system can be used to
measure the expression of ARV7 (androgen receptor splice variant 7)
transcripts in later stage prostate cancer patients.
The research has been published in Clinical Chemistry. A copy of
the publication is available on ANGLE's website here
https://angleplc.com/library/publications/.
Measurement of the expression of ARV7 on circulating tumor cells
(CTCs) obtained from a blood test(1) has previously been studied
and found to correlate with patient response to novel hormone
therapy (NHT) drugs (Enzalutamide and Abiraterone). Where ARV7 is
positively expressed, patients are unlikely to respond to NHT and
benefit from moving directly to taxane-based chemotherapies. Where
ARV7 is not expressed, patients do better when receiving NHT first
and only moving to chemotherapy subsequently.
Researchers believe that an ARV7 test utilising the Parsortix
system for CTC enrichment could provide key advantages over other
approaches. These include:
-- the ability to analyse mesenchymal CTCs, so called CK
(cytokeratin) negative cells, which are not captured by other CTC
systems. In their research, UKE, Graz and SciLifeLab found a
population of CK negative ARV7 positive cells that would not have
been detected with the other label-dependent enrichment methods
tested.
-- the ability to analyse the number of ARV7 transcripts on each
CTC. Existing approaches are limited to the presence or absence of
ARV7 in the whole population of cells or require elaborate
technologies to isolate CTCs that are available only at a small
number of specialised centres.
-- the ability to analyse the proportion of CTCs with ARV7
transcripts. Using the Parsortix system, researchers were able to
enumerate the numbers of CTCs with and without ARV7.
Cancer is a heterogeneous disease and this increased level of
resolution in analysis of ARV7 could add important understanding of
how best to treat the patient.
Independent research has also suggested that, in addition to
improved patient outcomes, avoiding the use of expensive NHT drugs
when the patient is ARV7 positive has the potential to reduce the
cost for healthcare resources. A cost-benefit analysis published in
the Journal of Clinical Oncology estimated that an ARV7 test
costing $1,000 per patient would result in cost savings averaging
$5,000 per patient, with cost saving of at least $20,000 per
patient with a positive ARV7 result.
Dr Amin El-Heliebi, Principal Investigator, Medical University
of Graz, commented:
"Use of the Parsortix system has, for the first time to our
knowledge, made it possible to investigate the number of cells
expressing the ARV7 transcript as a proportion of the total number
of CTCs and for the first time it has been possible to investigate
the number of ARV7 transcripts on a particular cell. This approach
may allow us to improve clinical performance in this key area of
prostate cancer treatment."
ANGLE's Founder and Chief Executive, Andrew Newland, added:
"The measurement of ARV7 in later stage prostate cancer patients
is one of a few accepted clinical uses of CTCs and is already
offered as a laboratory-developed test by a small number of
centres. We believe that the Parsortix system has specific
advantages in measurement of ARV7 and has the potential for wide
adoption in therapy selection."
1. ARV7 analysis requires the investigation of CTCs as
undertaken by the Parsortix system and cannot be undertaken using
the alternative ctDNA approach utilised by other companies.
For further information ANGLE:
ANGLE plc +44 (0) 1483 343434
Andrew Newland, Chief Executive
Ian Griffiths, Finance Director
finnCap Ltd (NOMAD and Joint
Broker)
Corporate Finance - Adrian
Hargrave, Simon Hicks, Kate
Bannatyne
Corporate Broking - Alice Lane,
Nikita Jain +44 (0)20 7220 0500
WG Partners (Joint Broker)
Nigel Barnes, Nigel Birks,
Andrew Craig, Chris Lee +44 (0) 203 705 9330
FTI Consulting
Simon Conway, Mo Noonan, Stephanie
Cuthbert +44 (0) 203 727 1000
Kimberly Ha (US) +1 212 850 5612
For Frequently Used Terms, please see the Company's website on
http://www.angleplc.com/the-parsortix-system/glossary/
This announcement contains inside information.
Notes for editors
About ANGLE plc www.angleplc.com
ANGLE is a world leading liquid biopsy company with sample to
answer solutions. ANGLE's proven patent protected platforms include
an epitope-independent circulating tumor cell (CTC) harvesting
technology and a downstream analysis system for cost effective,
highly multiplexed analysis of nucleic acids and proteins.
ANGLE's cell separation technology is called the Parsortix(TM)
system and it enables a liquid biopsy (simple blood test) to be
used to provide the cells of interest. Parsortix is the subject of
granted patents in Europe, the United States, Canada, India, China,
Japan and Australia and three extensive families of patents are
being progressed worldwide. The system is based on a microfluidic
device that captures live cells based on a combination of their
size and compressibility. The Parsortix system has a CE Mark for
Europe and FDA clearance is in process for the United States.
ANGLE's analysis technology for proteins and nucleic acids of
all types is based on a patented flow through array technology. It
provides for highly multiplexed, rapid and sensitive capture of
targets from a wide variety of sample types. A proprietary
chemistry allows for the capture and amplification of over 100
biomarkers simultaneously in a single reaction. These technologies
can be combined to provide fully automated, sample to answer
results in both centralized laboratory and point of use cartridge
formats. It is ideal for measuring gene expression and other
markers directly from Parsortix harvests.
ANGLE has established formal collaborations with world-class
cancer centres. These Key Opinion Leaders are working to identify
applications with medical utility (clear benefit to patients), and
to secure clinical data that demonstrates that utility in patient
studies. Details are available here
http://www.angleplc.com/the-company/collaborators/
The analysis of the cells that can be harvested from patient
blood with ANGLE's Parsortix system has the potential to help
deliver personalised cancer care offering profound improvements in
clinical and health economic outcomes in the treatment and
diagnosis of various forms of cancer.
The global increase in cancer to a 1 in 3 lifetime incidence is
set to drive a multi-billion dollar clinical market. The Parsortix
system is designed to be compatible with existing major medtech
analytical platforms and to act as a companion diagnostic for major
pharma in helping to identify patients that will benefit from a
particular drug and then monitoring the drug's effectiveness.
As well as cancer, the Parsortix technology has the potential
for deployment with several other important cell types in the
future. ANGLE biomarker analysis platforms are adaptable to measure
protein and nucleic acid biomarkers across the full spectrum of
disease applications.
ANGLE stock trades on the AIM market of the London Stock
Exchange under the ticker symbol AGL and in New York on the OTC-QX
under the ticker symbol ANPCY. For further information please
visit: www.angleplc.com
This information is provided by RNS
The company news service from the London Stock Exchange
END
MSCEAXFXEFLPEFF
(END) Dow Jones Newswires
January 08, 2018 02:00 ET (07:00 GMT)
Angle (LSE:AGL)
Historical Stock Chart
From Mar 2024 to Apr 2024
Angle (LSE:AGL)
Historical Stock Chart
From Apr 2023 to Apr 2024